Pharmacotherapy Obesity pharmacotherapy has recently experienced a revolution with the advent of glucagon-like-peptide (GLP)-1 agonists (for example, semaglutide), and subsequently multi-incretin receptor agonists including dual agonists (for example, gastric inhibitory polypeptide (GIP) analogue and a GLP-1 receptor agonist, Tirzepatide) and triple agonists (for example, GLP-1, GIP, and glucagon receptor (GCGR), Retatrutide)
Self-reported ratings tend to skew higher because unhappy customers are less likely to leave reviews on the company own platform
Guaranteed effective with no harmful side effects
Additionally, the trial was conducted in patients with type 2 diabetes rather than individuals with obesity alone, which may influence generalizability
Proc Am Assoc Can Res 43:594, 2002
Moving to an every-other-week schedule (every 14 days) would mean the concentration of the medication in your body drops significantly lower than intended